Amylyx Pharmaceuticals, Inc.
AMLX
Peringkat dalam Saham
#4349
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$28.83
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$3.62B
Perubahan (1 hari)
5.49%
Perubahan (1 tahun)
88.56%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Jumlah saham beredar untuk Amylyx Pharmaceuticals, Inc. (AMLX)
Jumlah saham beredar per June 2026: 111.20M
Menurut laporan keuangan terbaru dan harga saham Amylyx Pharmaceuticals, Inc., jumlah saham beredar saat ini adalah 111.20M. Pada akhir December 2023, perusahaan memiliki 67.23M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Amylyx Pharmaceuticals, Inc. (AMLX) dari 2019 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 111.20M | 63.18% |
| 2024 | 68.14M | 1.35% |
| 2023 | 67.23M | 1.09% |
| 2022 | 66.51M | 14.95% |
| 2021 | 57.86M | 2.48% |
| 2020 | 56.47M | 0.00% |
| 2019 | 56.47M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 128.33% |
US
|
|
| 396.00M | 256.13% |
US
|
|
| 478.91M | 330.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -44.08% |
NL
|
